{"id":2056974,"date":"2021-12-14T12:01:00","date_gmt":"2021-12-14T10:01:00","guid":{"rendered":"http:\/\/nhub.news\/?p=2056974"},"modified":"2021-12-15T05:55:13","modified_gmt":"2021-12-15T03:55:13","slug":"a-year-after-first-covid-19-vaccine-heres-whats-next-for-researchers-and-what-worries-them","status":"publish","type":"post","link":"http:\/\/nhub.news\/fr\/2021\/12\/a-year-after-first-covid-19-vaccine-heres-whats-next-for-researchers-and-what-worries-them\/","title":{"rendered":"A year after first COVID-19 vaccine, here's what's next for researchers \u2013 and what worries them"},"content":{"rendered":"

It’s the one year anniversary of the first COVID-19 vaccine, so what’s next for researchers? Here are some things to watch for \u2026<\/b>
\nIt’s the one year anniversary of the first COVID-19 vaccine, so what’s next for researchers? Here are some things to watch for the vaccine’s future. Pfizer and its partner BioNTech tested how well vaccine-produced antibodies could neutralize omicron. They found significant weakening after the standard two doses of their COVID-19 vaccine, but a booster increased antibody levels by 25-fold. (Dec.8)<\/p>\n